Our Pipeline

AZEDRA® (iobenguane I 131) is a radiotherapeutic for unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy.  AZEDRA was approved by the FDA on July 30, 2018 for the treatment in the U.S. of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. MORE>

RELISTOR^® subcutaneous injection, a small-molecule mu-opioid receptor antagonist, is approved in the United States for the treatment of opioid induced constipation in adult patients with chronic non-cancer pain. Progenics has licensed Relistor^® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. in markets worldwide.

RELISTOR^® Tablets (methylnaltrexone bromide) is approved in the U.S. for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Progenics has licensed Relistor® to Salix Pharmaceuticals, Inc., a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. in markets worldwide.

1404 is a technetium-99m labeled small molecule which binds PSMA and is used as an imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases. We have completed enrollment in a multi-center, open-label Phase 3 trial. The trial was designed to determine the sensitivity and specificity of 1404 to correctly identify whether or not patients have clinically significant prostate cancer (generally, Gleason score >3+4). MORE>

PyL (also known as 18F-DCFPyL) is a fluorinated PSMA-targeted Positron Emission Topography (“PET”) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. In June 2018, we completed enrollment in a Phase 2/3 trial to assess the diagnostic performance of PyL PET/CT imaging to detect prostate cancer in patients with recurrent and/or metastatic disease. In 2016, we launched PyLResearch Access ProgramTM making limited doses of PyL available to researchers. MORE>

1095 is a PSMA-targeted Iodine-131 labeled small molecule that is designed to deliver a dose of beta radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. In collaboration with Memorial Sloan-Kettering Cancer Center, an Investigational New Drug (“IND”) application has been filed in the U.S. and a Phase 1 trial has been initiated. MORE>

PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic. The PSMA TTC is designed to deliver a dose of alpha radiation directly to prostate cancer cells with minimal impact on the surrounding healthy tissues. In April 2018, we granted Bayer exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with Bayer’s alpha-emitting radionuclides.

PSMA AI is an imaging analysis technology, which uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging. Data from the Company’s Phase 1 and 2 studies of 1404 was used to develop a deep learning algorithm for the purpose of the automatic detection and quantification of 1404 uptake from SPECT/CT images as compared to a manual process.

PRO 140 is a humanized anti-CCR5 monoclonal antibody created at Progenics and now developed by CytoDyn, Inc. PRO 140 is in Phase 3 testing as a treatment for human immunodeficiency virus (HIV) infection.  MORE>